1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
170.14 USD   -2.24%
05:46aANALYST RECOMMENDATIONS : Coca-Cola, Dollar General, Comcast, Deliveroo, Seagen...
MS
05:15aSVB Securities Adjusts Seagen's Price Target to $152 From $159, Keeps Outperform Rating
MT
02:54aJapan Index Rallies on Upbeat Economic Reports; Daiichi Sankyo Soars 14% on Legal Victory
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck in advanced talks to buy Seagen in $40-billion deal - WSJ

07/06/2022 | 10:51pm EDT
Seagen's drug Tukysa

(Reuters) - Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly $40 billion or more, the Wall Street Journal reported on Wednesday.

The companies are discussing a price above $200 a share for Seagen, the report said, citing people familiar with the matter.

Shares of Seagen, which declined to comment on the report, closed at $175 on Wednesday. Merck did not immediately respond to Reuters request for comment outside business hours.

Merck and Seagen are seeking to seal a deal on or before the announcement of Merck's second fiscal-quarter earnings set for July 28, the WSJ report said.

(Reporting by Shivam Patel in Bengaluru; Editing by Arun Koyyur)


© Reuters 2022
All news about SEAGEN INC.
05:46aANALYST RECOMMENDATIONS : Coca-Cola, Dollar General, Comcast, Deliveroo, Seagen...
MS
05:15aSVB Securities Adjusts Seagen's Price Target to $152 From $159, Keeps Outperform Rating
MT
02:54aJapan Index Rallies on Upbeat Economic Reports; Daiichi Sankyo Soars 14% on Legal Victo..
MT
02:38aNikkei hits over 7-month high on Wall Street optimism, robust earnings
RE
08/14Japanese shares rise on Wall Street optimism, strong earnings
RE
08/14Daiichi Sankyo Shares Gain After It Wins Dispute Over Cancer Drug Technology
DJ
08/12SEAGEN : Statement on Outcome of Daiichi Sankyo Arbitration - Form 8-K
PU
08/12SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/12Seagen Loses Arbitration Against Daiichi Sankyo; Sees No Impact on Existing Business
MT
08/12Seagen loses arbitration against Daiichi Sankyo over drug technology
RE
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 841 M - -
Net income 2022 -639 M - -
Net cash 2022 1 472 M - -
P/E ratio 2022 -49,0x
Yield 2022 -
Capitalization 31 380 M 31 380 M -
EV / Sales 2022 16,2x
EV / Sales 2023 11,8x
Nbr of Employees 2 675
Free-Float 99,2%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 170,14 $
Average target price 182,62 $
Spread / Average Target 7,33%
EPS Revisions
Managers and Directors
Roger D. Dansey Chief Executive & Medical Officer
Todd E. Simpson Chief Financial Officer
Felix James Baker Chairman
Vaughn B. Himes Chief Technical Officer
David W. Gryska Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.10.05%31 380
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068
CELLTRION, INC.5.05%21 967